IOVA vs. CORT

In the year-to-date period, IOVA achieves a -57.16% return, which is significantly lower than CORT's 41.66% return. Over the past 10 years, IOVA has underperformed CORT with an annualized return of -11.50%, while CORT has yielded a comparatively higher 28.81% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Iovance Biotherapeutics, Inc. (IOVA) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current IOVA Sharpe Ratio is -1.02, which is lower than the CORT Sharpe Ratio of 1.50. The chart below compares the historical Sharpe Ratios of IOVA and CORT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither IOVA nor CORT has paid dividends to shareholders.

The maximum IOVA drawdown since its inception was -99.37%, which is greater than CORT's maximum drawdown of -94.28%. Use the drawdown chart below to compare losses from any high point for IOVA and CORT. For additional features, visit the drawdowns tool.

Iovance Biotherapeutics, Inc. (IOVA) has a higher volatility of 26.25% compared to Corcept Therapeutics Incorporated (CORT) at 16.59%. This indicates that IOVA's price experiences larger fluctuations and is considered to be riskier than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Iovance Biotherapeutics, Inc. and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.